Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03562273 · ClinicalTrials.gov registry record
GammaPod Registry and Quality of Life Nomogram
A clinical trial of Breast Cancer Female, sponsored by University of Maryland, Baltimore.
- Recruiting
- Registry status
- 160
- Enrollment target
- 4
- Study locations
NCT03562273 is a study of Breast Cancer Female that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 160 participants, below the 689-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (77% lower). The trial reports 4 study locations across 2 states.
The verdict
NCT03562273, a study of Breast Cancer Female, is actively recruiting participants, sponsored by University of Maryland, Baltimore.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
Conditions Studied
Interventions
- RADIATION Quality Of Life Sizing Nomogram
Study Locations (4)
Maryland
- Upper Chesapeake Health - Bel Air
- Central Maryland Oncology Center - Columbia
- Baltimore Washington Medical Center - Glen Burnie
Texas
- UTSouthwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-01-03 |
| Est. Completion | 2030-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03562273
The ClinicalTrials.gov registry entry for NCT03562273 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 689-participant average among 46 other Breast Cancer Female trials with a reported enrollment target (77% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer Female appearing as the primary indexed condition, and to 1 intervention - of which Quality Of Life Sizing Nomogram is the first listed.
NCT03562273 reports 4 study locations spanning 2 distinct geographic areas - top geographies include Maryland, Texas.
Frequently Asked Questions
What is clinical trial NCT03562273 about?
NCT03562273 is a clinical study titled "GammaPod Registry and Quality of Life Nomogram". This study is a prospective, single arm study (registry) summarizing patient-level adverse-event and tumor outcomes as well as a number of feasibility and dosimetric characteristics of delivering a single-fraction boost with the GammaPod.
What is the current status of trial NCT03562273?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2019-01-03. Estimated completion is 2030-12.
What conditions does trial NCT03562273 study?
This clinical trial studies the following conditions: Breast Cancer Female.
What interventions are being tested in trial NCT03562273?
The interventions under investigation include: Quality Of Life Sizing Nomogram (RADIATION).
Who is sponsoring clinical trial NCT03562273?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03562273 being conducted?
This trial has 4 study locations across Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Resiliency Through Exercise Program (B-REP)
RECRUITING · NA
-
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.